Immune Activation by Epidermal Growth Factor Receptor–Specific Monoclonal Antibody Therapy for Head and Neck Cancer

Abstract

To determine if the epidermal growth factor receptor (EGFR)-specific monoclonal antibodies (mAbs) cetuximab or panitumumab mediate in vitro immune activation against squamous cell carcinoma of the head and neck (SCCHN) cell lines.

Lack of in Vivo Antibody Dependent Cellular Cytotoxicity with Antibody Containing Gold Nanoparticles

“…The H1975 cells remained viable in the presence of all antibodies and antibody containing AuNPs (Supporting Information, Figure S1) 72 h post-treatment. The results are consistent with previous reports that show no in vitro cell death upon exposure of H1975 lung cancer cells to cetuximab or panitumumab and reveal that multiple antibodies on the surface of the AuNPs also do not produce any antiproliferative effects in vitro.…”

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

“…In the present study, we extended our previous observations that cetuximab mediates cell-dependent cytotoxicity against SCCHN cells [11]. We found that the expression of an Fc γ R IIIa-158 V allele correlates strongly with ADCC activity, NK cell activation, degranulation and secretion of several cytokines with anti-tumor activity.…”

Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients

“…Indeed, panitumumab has been shown to bind the EGFR with an 8-fold greater affinity than cetuximab (23). Based on our prior studies (9) and this study using HNSCC cells, we observed that both panitumumab and cetuximab bind to EGFR and HNSCC cells with similar dilution curves and, importantly, both mAbs appeared to inhibit EGFR internalization and ligand-induced activation at similar doses. Thus, EGFR binding affinity is of uncertain clinical significance.…”